Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3660619 | 1.00 | CYP2C9 (0.33) | CYP2C9TDP1RAB9AALDH1A1APP | |
| SCHEMBL963660 | 0.78 | CYP2C9 (0.49) | CYP2C9RAB9AALDH1A1KDM4EKMT2A | |
| SCHEMBL963659 | 0.78 | CYP2C9 (0.49) | CYP2C9RAB9AALDH1A1KDM4EKMT2A | |
| SCHEMBL13590567 | 0.78 | CYP2C9 (0.49) | CYP2C9RAB9AALDH1A1KDM4EKMT2A | |
| SCHEMBL14629838 | 0.78 | CYP2C9 (0.37) | CYP2C9RAB9AALDH1A1APPKDM4E | |
| SCHEMBL14629840 | 0.78 | CYP2C9 (0.37) | CYP2C9RAB9AALDH1A1APPKDM4E | |
| SCHEMBL14396678 | 0.78 | CYP2C9 (0.37) | CYP2C9RAB9AALDH1A1APPKDM4E | |
| SCHEMBL9473889 | 0.77 | CYP2C9 (0.36) | CYP2C9TDP1RAB9AALDH1A1APP | |
| SCHEMBL28572087 | 0.77 | MCL1 (0.47) | CYP2C9TDP1RAB9AALDH1A1APP | |
| SCHEMBL9473882 | 0.77 | CYP2C9 (0.36) | CYP2C9TDP1RAB9AALDH1A1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292482-A1 | NOVEL PRECURSORS | BIAL -Portela & CA.., S.A. | 2010-11-18 | — | — | US | disclosed |
| EP-2217571-A2 | NOVEL PRECURSORS | BIAL - Portela & Ca., S.A. (PT) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009054742-A2 | NOVEL PRECURSORS | BIAL - PORTELA & CA., S.A. (PT) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292482-A1 | NOVEL PRECURSORS | CBR3, CBR1, C1R | CYP2C9 322/4885TDP1 4463/4885RAB9A 1608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.